2019
Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology
Bikdeli B, McAndrew T, Crowley A, Chen S, Mehdipoor G, Redfors B, Liu Y, Zhang Z, Liu M, Zhang Y, Francese DP, Erlinge D, James SK, Han Y, Li Y, Kastrati A, Schüpke S, Stables RH, Shahzad A, Steg PG, Goldstein P, Frigoli E, Mehran R, Valgimigli M, Stone GW. Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. Thrombosis And Haemostasis 2019, 120: 348-362. PMID: 31820428, PMCID: PMC7040882, DOI: 10.1055/s-0039-1700872.Peer-Reviewed Original ResearchMeSH KeywordsAlgorithmsAnticoagulantsData Interpretation, StatisticalDatabases, FactualDrug Administration ScheduleHeparinHirudinsHumansMedical InformaticsMyocardial InfarctionOutcome Assessment, Health CarePeptide FragmentsPercutaneous Coronary InterventionRandomized Controlled Trials as TopicRecombinant ProteinsRiskTreatment OutcomeConceptsPercutaneous coronary interventionAcute myocardial infarctionMyocardial infarctionIndividual patient databaseProlonged bivalirudin infusionSegment elevation MIIndividual patient dataPatient-level dataDifferent relative risksConsensus-based definitionBivalirudin infusionPeriprocedural anticoagulationAnticoagulation regimenCoronary interventionElevation MIFemoral accessRandomized trialsPatient groupOutcome definitionsRelative riskPrespecified criteriaBivalirudinTrial publicationsST segmentPatient database
2016
Dedicated Bifurcation Stent for the Treatment of Bifurcation Lesions Involving Large Side Branches Outcomes From the Tryton Confirmatory Study
Généreux P, Kumsars I, Schneider JE, Lesiak M, Redfors B, Cornelis K, Selmon MR, Dens J, Hoye A, Metzger DC, Muyldermans L, Slagboom T, Francese DP, Ayele GM, Laak LL, Bartorelli AL, Cutlip DE, Kaplan AV, Leon MB. Dedicated Bifurcation Stent for the Treatment of Bifurcation Lesions Involving Large Side Branches Outcomes From the Tryton Confirmatory Study. JACC Cardiovascular Interventions 2016, 9: 1338-1346. PMID: 27388820, DOI: 10.1016/j.jcin.2016.03.042.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryBiomarkersChromium AlloysCoronary AngiographyCoronary Artery DiseaseCoronary StenosisCoronary VesselsCreatine Kinase, MB FormEuropeFemaleHumansMaleMiddle AgedMyocardial InfarctionProspective StudiesProsthesis DesignRisk FactorsStentsTime FactorsTreatment OutcomeUnited StatesConceptsTryton Side Branch StentPeriprocedural myocardial infarctionSide Branch StentPivotal RCTsLarge side branchesPrimary endpointMyocardial infarctionBranch StentConfirmatory studiesBifurcation lesionsSide branchesProvisional side branchDedicated bifurcation stentsStent armOnly patientsAngiographic parametersCoronary artery bifurcationsPatientsRCTsSmall side branchesInfarctionOverall trialBifurcation stentsArtery bifurcationPre-defined performance goalSafety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials
Giustino G, Mehran R, Bansilal S, Feit F, Lincoff M, Deliargyris EN, Kirtane AJ, Généreux P, Redfors B, Prats J, Bernstein D, Brener SJ, Skerjanec S, Lansky AJ, Francese DP, Dangas GD, Stone GW. Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials. The American Journal Of Cardiology 2016, 118: 6-16. PMID: 27181566, DOI: 10.1016/j.amjcard.2016.04.005.Peer-Reviewed Original ResearchConceptsGlycoprotein IIb/IIIa inhibitorsPercutaneous coronary interventionMajor adverse cardiac eventsEfficacy of bivalirudinAdverse cardiac eventsDiabetes mellitusMajor bleedingCoronary interventionBivalirudin treatmentCause mortalityCardiac eventsNon-coronary artery bypass graft-related major bleedingPrimary efficacy end pointPrimary safety end pointUrgent Intervention Triage StrategyAcute Myocardial Infarction trialIIb/IIIa inhibitorsEnd pointHORIZONS-AMI trialPCI Linking AngiomaxComposite of deathEfficacy end pointMyocardial Infarction trialSafety end pointPatient-level data
2015
Reasonable incomplete revascularisation after percutaneous coronary intervention: the SYNTAX Revascularisation Index.
Généreux P, Campos CM, Yadav M, Palmerini T, Caixeta A, Xu K, Francese DP, Dangas GD, Mehran R, Leon MB, Serruys PW, Stone GW. Reasonable incomplete revascularisation after percutaneous coronary intervention: the SYNTAX Revascularisation Index. EuroIntervention 2015, 11: 634-42. PMID: 25308300, DOI: 10.4244/eijy14m10_05.Peer-Reviewed Original ResearchMeSH KeywordsAgedArea Under CurveChi-Square DistributionCoronary AngiographyCoronary Artery DiseaseDecision Support TechniquesFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPercutaneous Coronary InterventionPredictive Value of TestsProportional Hazards ModelsProspective StudiesRisk AssessmentRisk FactorsROC CurveTime FactorsTreatment OutcomeConceptsResidual SYNTAX scorePercutaneous coronary interventionBaseline SYNTAX scoreOne-year mortalityCoronary artery diseaseCAD burdenIncomplete revascularisationSYNTAX scoreCoronary interventionOne-year adverse outcomesResidual coronary artery diseaseNew prognostic instrumentPrediction of deathAngiograms of patientsBetter prognostic accuracyDegree of revascularisationACUITY trialArtery diseaseIndependent predictorsMultivariable analysisAdverse outcomesWorse outcomesPrognostic accuracyPrognostic instrumentPatientsOutcomes of a dedicated stent in coronary bifurcations with large side branches: A subanalysis of the randomized TRYTON bifurcation study
Généreux P, Kini A, Lesiak M, Kumsars I, Fontos G, Slagboom T, Ungi I, Metzger DC, Wykrzykowska JJ, Stella PR, Bartorelli AL, Fearon WF, Lefèvre T, Feldman RL, Tarantini G, Bettinger N, Minalu Ayele G, LaSalle L, Francese DP, Onuma Y, Grundeken MJ, Garcia-Garcia HM, Laak LL, Cutlip DE, Kaplan AV, Serruys PW, Leon MB. Outcomes of a dedicated stent in coronary bifurcations with large side branches: A subanalysis of the randomized TRYTON bifurcation study. Catheterization And Cardiovascular Interventions 2015, 87: 1231-1241. PMID: 26397982, DOI: 10.1002/ccd.26240.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCoronary AngiographyCoronary Artery DiseaseCoronary StenosisCoronary ThrombosisFemaleHumansMaleMiddle AgedMyocardial InfarctionProspective StudiesProsthesis DesignRisk FactorsSeverity of Illness IndexSingle-Blind MethodStentsTime FactorsTreatment OutcomeConceptsPrimary end pointPercent diameter stenosisLarge side branchesBifurcation lesionsEnd pointDiameter stenosisMyocardial infarctionSegment percent diameter stenosisPeri-procedural myocardial infarctionAngiographic percent diameter stenosisSide branchesProvisional groupTarget vessel failureTarget vessel revascularizationTrue bifurcation lesionsComplex bifurcation lesionsNon-inferiority marginProvisional stenting strategyPrimary endpointVessel revascularizationTrial cohortCardiac deathTreatment strategiesProvisional stentingSB diameter
2014
Clinical profile and impact of family history of premature coronary artery disease on clinical outcomes of patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: analysis from the HORIZONS-AMI Trial
Ertelt K, Généreux P, Mintz GS, Brener SJ, Kirtane AJ, McAndrew TC, Francese DP, Ben-Yehuda O, Mehran R, Stone GW. Clinical profile and impact of family history of premature coronary artery disease on clinical outcomes of patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: analysis from the HORIZONS-AMI Trial. Cardiovascular Revascularization Medicine 2014, 15: 375-380. PMID: 25288517, DOI: 10.1016/j.carrev.2014.09.002.Peer-Reviewed Original ResearchConceptsPremature coronary artery diseaseST-elevation myocardial infarctionPrimary percutaneous coronary interventionCoronary artery diseaseHORIZONS-AMI trialPercutaneous coronary interventionFamily historyCoronary interventionArtery diseaseIndependent predictorsClinical outcomesClinical profileMyocardial infarctionFinal TIMI 3 flowMyocardial blush grade 2Less diabetes mellitusTIMI 3 flowFuture cardiovascular eventsPrognosis of patientsShorter symptom onsetMore dyslipidemiaCardiovascular eventsCurrent smokersSymptom onsetDiabetes mellitus